[
  {
    "page_number": 4,
    "row_name": "amikacin",
    "superscript_number": "1,2,3",
    "ph_value": "3.5-5.5",
    "column_name": "Local site pain on Infusion",
    "mark_type": "circle"
  },
  {
    "page_number": 4,
    "row_name": "ampicillin",
    "superscript_number": "4,5,6,7",
    "ph_value": "8.0-10.0",
    "column_name": "Phlebitis.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "ampicillin and sulbactam",
    "superscript_number": "8,9",
    "ph_value": "8.0-10.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "azithromycin",
    "superscript_number": "1,9",
    "ph_value": "NR*",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "aztreonam",
    "superscript_number": "1,10",
    "ph_value": "4.5-7.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "aztreonam and avibactam sodium",
    "superscript_number": "11",
    "ph_value": null,
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "capreomycin",
    "superscript_number": "12,13",
    "ph_value": "4.0-8.0",
    "column_name": "Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "cefazolin",
    "superscript_number": "1,14",
    "ph_value": "4.5-7.0",
    "column_name": "Phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "cefepime",
    "superscript_number": "1,15",
    "ph_value": "4.0-6.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "cefiderocol sulfate tosylate",
    "superscript_number": "1,16,17",
    "ph_value": "5.2-5.8",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "cefotaxime sodium",
    "superscript_number": "1,18,19",
    "ph_value": "5.0-7.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "cefotetan disodium",
    "superscript_number": "1,20",
    "ph_value": "4.5-6.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "cefoxitin",
    "superscript_number": "1,21",
    "ph_value": "4.2-7.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "cefoperazone",
    "superscript_number": "1,22,23",
    "ph_value": "4.5-6.5",
    "column_name": "Phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "ceftaroline fosamil",
    "superscript_number": "1,24",
    "ph_value": "4.8-6.5",
    "column_name": "Phlebitis.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.diamond"
  },
  {
    "page_number": 4,
    "row_name": "ceftazidime",
    "superscript_number": "1,25",
    "ph_value": "5.0-8.0",
    "column_name": "Phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 5,
    "row_name": "amikacin",
    "row_superscript": null,
    "statement": "Do not physically premix with other drugs; administer separately as recommended by manufacturer. Inactivated in solution with beta-lactam antibiotics (e.g., cephalosporins, penicillins) and vancomycin. Do not mix in the same solution. Appropriate spacing required because of physical incompatibilities.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "ampicillin",
    "row_superscript": "4,5,6,7",
    "statement": "Ampicillin solutions should always be administered separately, unless compatibility with other infusion solutions or medicines has been established. Ampicillin solutions should not be mixed with aminoglycosides, metronidazole and injectable tetracycline derivatives such as oxytetracycline, rolitetracycline and doxycycline. Visual signs of incompatibility are precipitation, clouding and discoloration.6",
    "statement_superscript": "6",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "ampicillin and sulbactam",
    "row_superscript": "8,9",
    "statement": "Frequently used concomitantly with aminoglycosides (e.g., gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer at separate sites.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "azithromycin",
    "row_superscript": "1,9",
    "statement": "Manufacturer states, \"Other IV substances, additives, or medications should not be added to azithromycin, or infused simultaneously through the same IV line.\" Flush IV line with a compatible IV fluid before and after administration. ¹ Local IV site reactions have been reported with the intravenous administration of azithromycin. All volunteers who received infusate concentrations above 2.0 mg/mL experienced local IV site reactions and, therefore, higher concentrations should be avoided. 9",
    "statement_superscript": "1.9",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "aztreonam",
    "row_superscript": "1,10",
    "statement": "Do not infuse simultaneously with other drugs or solutions except in proven compatibility.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "aztreonam and avibactam sodium",
    "row_superscript": "11",
    "statement": "Emblaveo is administered by intravenous infusion over 3 hours. This medicinal product must not be mixed with other medicinal products except sodium chloride (0.9%) solution for injection, glucose (5%) solution for injection, or Lactated Ringer's solution as mentioned below.11",
    "statement_superscript": "11",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "capreomycin",
    "row_superscript": "12,13",
    "statement": null,
    "statement_superscript": null,
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "cefazolin",
    "row_superscript": "1,14",
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush IV line before and after administration.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "cefepime",
    "row_superscript": "1,15",
    "statement": "Temporarily discontinuing other solutions infusing at the same site during intermittent infusion. May be used concomitantly with aminoglycosides (e.g., gentamicin, tobramycin), aminophylline, metronidazole, and vancomycin, but these drugs must never be mixed in the same infusion (mutual inactivation or other potential interactions). If concurrent therapy with cefepime is indicated, each of these antibiotics can be administered separately.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "cefiderocol sulfate tosylate",
    "row_superscript": "1,16,17",
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "cefotaxime sodium",
    "row_superscript": "1,18,19",
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "cefotetan disodium",
    "row_superscript": "1,20",
    "statement": "Solutions of cefotetan must not be admixed with solutions containing aminoglycosides. If Cefotan and aminoglycosides are to administered to the same patient, they must be administered separately and not as a mixed injection.20",
    "statement_superscript": "20",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "cefoxitin",
    "row_superscript": "1,21",
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "cefoperazone",
    "row_superscript": "1,22,23",
    "statement": "Solutions of CEFOBID and aminoglycoside should not be directly mixed, since there is a physical incompatibility between them.22",
    "statement_superscript": "22",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "ceftaroline fosamil",
    "row_superscript": "1,24",
    "statement": "Manufacturer states, Should not be mixed with or physically added to solutions containing other drugs.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 5,
    "row_name": "ceftazidime",
    "row_superscript": "1,25",
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin, and tobramycin), but these drugs must never be mixed in the same infusion (mutual inactivation). May exhibit a physical incompatibility with vancomycin depending on concentration. If aminoglycosides or vancomycin are given concurrently, administer separately and flush IV line before and after administration. Manufacturer recommends temporarily discontinuing other solutions infusing at the same site during intermittent infusion and states, \"Do not add supplementary medications to premixed plastic IV containers.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 6,
    "row_name": "ceftizoxime",
    "superscript_number": "26,27",
    "ph_value": null,
    "column_name": "Phlebitis.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "ceftobiprole medocaril sodium",
    "superscript_number": "1,28,29",
    "ph_value": "4.5-5.5",
    "column_name": "Phlebitis.Thrombosis of vessel.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "ceftolozane/tazobactam",
    "superscript_number": "1,30",
    "ph_value": "5.0-7.0",
    "column_name": "Phlebitis.Thrombosis of vessel.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "ceftriaxone",
    "superscript_number": "1,31",
    "ph_value": "6.6-6.7",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "cefuroxime",
    "superscript_number": "1,32",
    "ph_value": "5.0-8.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "chloramphenicol sodium succinate",
    "superscript_number": "1,33",
    "ph_value": "6.4-7.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "ciprofloxacin",
    "superscript_number": "1,34",
    "ph_value": "3.5-4.6",
    "column_name": "Thrombo-phlebitis.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "clarithromycin",
    "superscript_number": "35",
    "ph_value": null,
    "column_name": "Phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "clindamycin",
    "superscript_number": "1,36",
    "ph_value": "5.5-7.0",
    "column_name": "Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "daptomycin",
    "superscript_number": "1,37,38",
    "ph_value": "6.8",
    "column_name": "No simultaneous infusion/dedicated lumen",
    "mark_type": "diamond"
  },
  {
    "page_number": 6,
    "row_name": "dalbavancin",
    "superscript_number": "1,39,40",
    "ph_value": null,
    "column_name": "Phlebitis.Thrombo-phlebitis.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "delafloxacin meglumine",
    "superscript_number": "1,41",
    "ph_value": "NR*",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Thrombosis of vessel.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "doripenem",
    "superscript_number": "42,43",
    "ph_value": "4.5-5.5",
    "column_name": "Phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "doxycycline hyclate",
    "superscript_number": "1,44",
    "ph_value": "1.8-3.3",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Thrombosis of vessel.Local site pain on Infusion.Redness at injection site.Absolute vein patency needed.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "eravacycline",
    "superscript_number": "1,45,46",
    "ph_value": "5.5-7.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Thrombosis of vessel.Local site pain on Infusion.Redness at injection site.Absolute vein patency needed.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "ertapenem",
    "superscript_number": "1,47",
    "ph_value": "7.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 6,
    "row_name": "erythromicin lactobionate",
    "superscript_number": "1,48",
    "ph_value": "6.5-7.7",
    "column_name": "Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "diamond.circle.circle.diamond"
  },
  {
    "page_number": 7,
    "row_name": "ceftizoxime",
    "row_superscript": "26,27",
    "statement": "Ceftizoxime is given as an injection into a muscle or a vein. Injection into a vein must be given slowly through an IV infusion, and can take up to 30 minutes to complete.26",
    "statement_superscript": "26",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "ceftobiprole medocaril sodium",
    "row_superscript": "1,28,29",
    "statement": "Incompatible with calcium-containing IV solutions; Precipitation may occur when mixed with calcium-containing solutions. Do not mix or simultaneously administer ceftobiprole and calcium-containing solutions in the same IV line.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "ceftolozane/ tazobactam",
    "row_superscript": "1,30",
    "statement": "Zerbaxa (ceftolozane/tazobactam) should not be infused simultaneously with other medications via the same intravenous line. 30",
    "statement_superscript": "30",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "ceftriaxone",
    "row_superscript": "1,31",
    "statement": "Ceftriaxone and calcium-containing solutions, including continuous calcium-containing infusions such as parenteral nutrition, should not be mixed or coadministered simultane- ously via a Y-site.\" However, in patients other than neonates, ceftriaxone and calcium-containing solutions may be administered sequentially if the infusion lines are thoroughly flushed between infusions with a compatible fluid. Manufacturer lists aminoglycosides (e.g., gentamicin), amsacrine, fluconazole, and vancomycin as incompatible and states, \"May be given sequentially with thorough flushing of the IV line with compatible solution between the administrations.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "cefuroxime",
    "row_superscript": "1,32",
    "statement": "May be used concomitantly with aminoglycosides (e.g., amikacin, gentamicin), but these drugs must never be mixed in the same infusion (mutual inactivation). If given concurrently, administer separately and flush the IV line before and after administration.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "chloramphenicol sodium succinate",
    "row_superscript": "1,33",
    "statement": null,
    "statement_superscript": null,
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "ciprofloxacin",
    "row_superscript": "1,34",
    "statement": "Manufacturer recommends temporarily discontinuing other solutions infusing at the same site during intermittent infusion through a Y-site or volume control and that ciprofloxacin be administered separately and the IV line be flushed before and after administration of any other drug.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "clarithromycin",
    "row_superscript": "35",
    "statement": "Clarithromycin 500 mg powder for solution for infusion should be administered into one of the larger proximal veins as an IV infusion over 60 minutes, using a solution concentra- tion of about 2 mg/ml. Clarithromycin should not be given as a bolus or an intramuscular injection.35",
    "statement_superscript": "35",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "clindamycin",
    "row_superscript": "1,36",
    "statement": "No incompatibility has been demonstrated with the antibiotics carbenicillin, cephalothin, gentamicin, kanamycin, or penicillin. Manufacturer lists as incompatible with aminophylline, ampicillin, barbiturates, calcium gluconate, magnesium sulfate, phenytoin. Should not be administered intravenously undiluted as a bolus.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "daptomycin",
    "row_superscript": "1,37,38",
    "statement": "Additives or other medications should not be added to daptomycin single-use vials or infusion bags, or infused simultaneously through the same intravenous. If the same intravenous line is used for sequential infusion of several different drugs, the line should be flushed with a compatible infusion solution before and after infusion with daptomycin.37",
    "statement_superscript": "37",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "dalbavancin",
    "row_superscript": "1,39,40",
    "statement": "Do not co-infuse dalbavancin with other medications or electrolytes. Saline-based infusion solutions may cause precipitation and should not be used. The compatibility of reconstituted dalbavancin with IV medications, additives, or substances other than D5W has not been established. A single dose as an infusion equally distributed over 30 minutes.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "delafloxacin meglumine",
    "row_superscript": "1,41",
    "statement": "Do not administer delafloxacin through the same IV line with any solution containing multivalen cations (e.g., calcium and magnesium). Do NOT co-infuse delafloxacin with other medications. May be given through a y-tube or three way stopcock of infusion set. Temporarily disconsinue other solutions infusing at the same site, and flush tubing with D5W or NS before and after delafloxacin. Monitor infusion site for inlammation and/or extravasation.¹ Do not administer Baxdela for Injection with any solution containing multivalent cations, e.g.,calcium and magnesium, through the same intravenous line Do not co-infuse Baxdela for Injection with other medications. If a common intravenous line is being used to administer other drugs in addition to Baxdela the line should be flushed before and after each Baxdela infusion with 0.9% Sodium Chloride Injection or D5W. Infusion site extravasation. Infusion related reactions. Baxdela should not be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line. 41",
    "statement_superscript": "1.41",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "doripenem",
    "row_superscript": "42,43",
    "statement": null,
    "statement_superscript": null,
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "doxycycline hyclate",
    "row_superscript": "1,44",
    "statement": "Avoid rapid adminstration. Duration of infusion may vary with dose but it is usually 1 to 4 hours. The recommended infusion time for 100 mg of a 0.5 mg/ml solution is 1 hour.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "eravacycline",
    "row_superscript": "1,45,46",
    "statement": "Eravacycline should not be mixed with other drugs or added to solutions containing other drugs; May be administered through a dedicated line or through a Y-site. If the same IV line is used for sequential infusion of several drugts, the line should be flushed with normal saline before and after the infusion.¹ Xerava may be administered intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of Xerava with 0.9% Sodium Chloride injection.46",
    "statement_superscript": "1.46",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "ertapenem",
    "row_superscript": "1,47",
    "statement": "Do not mix or co-infuse ertapenem with other medications. Do not use diluents containing dextrose.¹ \"Infusion site reactions\"¹ IV infusion over 30 minutes. 47",
    "statement_superscript": "1.47",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 7,
    "row_name": "erythromicin lactobionate",
    "row_superscript": "1,48",
    "statement": "Specific compatibilities dependent on concentration and manufacturer; consult a pharmacist. A slow infusion rate is recommended to reduce pain along the injection site. Continuous infusion preferred. Mild local venous discomfort.¹ Occasional venous irritation has been encountered, but if the infusion is given slowly, in dilute solution, preferably by continuous intravenous infusion or intermittent infusion in no less than 20 to 60 minutes, pain and vessel trauma are minimized.48",
    "statement_superscript": "1.48",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 8,
    "row_name": "fosfomycin",
    "superscript_number": "49",
    "ph_value": null,
    "column_name": "Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "flucloxacillin",
    "superscript_number": "50,51",
    "ph_value": null,
    "column_name": "Phlebitis.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "gentamicin sulfate",
    "superscript_number": "1,52",
    "ph_value": "3.0-5.5",
    "column_name": "Phlebitis.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "imipenem-cilastatin",
    "superscript_number": "1,53",
    "ph_value": "6.5-8.5",
    "column_name": "Phlebitis.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "meropenem and vaborbactam",
    "superscript_number": "1,54,55",
    "ph_value": null,
    "column_name": "Phlebitis.Thrombosis of vessel.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "netilmicin",
    "superscript_number": "55,57",
    "ph_value": "3.5-6.0",
    "column_name": "Phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "ofloxacin",
    "superscript_number": "58,59,60",
    "ph_value": "2-9",
    "column_name": "Phlebitis.Thrombosis of vessel.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "plazomicin",
    "superscript_number": "61,62",
    "ph_value": "6.5",
    "column_name": "No simultaneous infusion/dedicated lumen",
    "mark_type": "diamond"
  },
  {
    "page_number": 8,
    "row_name": "lefamulin",
    "superscript_number": "1,63",
    "ph_value": "4.5-5.5",
    "column_name": "Phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "levofloxacin",
    "superscript_number": "1,64,65",
    "ph_value": "3.8-5.8",
    "column_name": "Phlebitis.Thrombo-phlebitis.Thrombosis of vessel.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "lincomycin hydrochloride",
    "superscript_number": "1,66",
    "ph_value": "3.0-5.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "linezolid",
    "superscript_number": "1,67",
    "ph_value": "4.8",
    "column_name": "Phlebitis.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "meropenem",
    "superscript_number": "1,68",
    "ph_value": "7.3-8.3",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "metronidazole hydrochloride",
    "superscript_number": "1,69,70",
    "ph_value": "4.5-7.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "minocycline hydrochloride",
    "superscript_number": "1,71",
    "ph_value": "4.5-5.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain on Infusion.Redness at injection site.Absolute vein patency needed.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "moxifloxacin hydrochloride",
    "superscript_number": "1,72",
    "ph_value": "4.1-4.6",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 8,
    "row_name": "nafcillin sodium",
    "superscript_number": "1,73",
    "ph_value": "6-8.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 9,
    "row_name": "fosfomycin",
    "row_superscript": "49",
    "statement": "IVOZFO™ (fosfomycin for injection) must be reconstituted and diluted prior to administration. Use Dextrose 5% in Water (D5W) for reconstitution of the powder. It is not recommended to use Sodium Chloride containing solutions for reconstitution of IVOZFO™ due to their additional sodium load (See WARNINGS AND PRECAUTIONS). IVOZFO™™™ (fosfomycin for injection) is intended for intravenous administration. The duration of infusion should be at least 15 minutes for a 2 gram dose, 30 minutes for a 4 gram dose and 60 minutes for an 8 gram dose. Isolated reports from the literature indicate that extending the infusion time to up to 4 hours might reduce the risk of hypokalemia. In patients with high risk of hypokalemia, an extended infusion time (up to 4 hours for the 4g and 8g strengths) might be considered. Fosfomycin solutions should not be mixed together with other parenteral preparations. 49",
    "statement_superscript": "49",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "flucloxacillin",
    "row_superscript": "50,51",
    "statement": "It is advisable not to combine flucloxacillin with other drugs in solution for parenteral administration. 50",
    "statement_superscript": "50",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "gentamicin sulfate",
    "row_superscript": "1,52",
    "statement": "Do not physically premix with other drugs. Inactivated in solution with beta-lactam antibiotics and vancomycin. Appropriate spacing required because of incompatibilities.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "imipenem-cilastatin",
    "row_superscript": "1,53",
    "statement": "Do not mix with or physically add other antibiotics. May be given through y-tube or three-way stopcock of infusion set. Use small needles and large veins, and rotate infusion sites.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "meropenem and vaborbactam",
    "row_superscript": "1,54,55",
    "statement": "Only compatible with NS. A single dose as an infusion equally distributed over 3 hours.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "netilmicin",
    "row_superscript": "55,57",
    "statement": null,
    "statement_superscript": null,
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "ofloxacin",
    "row_superscript": "58,59,60",
    "statement": "Ofloxacin solution for infusion should be administered only by slow IV infusion over a period of 30-60 minutes. Fluoroquinolones, including ofloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid ofloxacin in patients with known history of myasthenia gravis. 60",
    "statement_superscript": "60",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "plazomicin",
    "row_superscript": "61,62",
    "statement": "Administer ZEMDRI 15 mg/kg every 24 hours by intravenous (IV) infusion over 30 minutes to patients 18 years of age or older with creatinine clearance greater than or equal to 90 mL/min. ZEMDRI should not be mixed with other drugs or physically added to solutions containing other drugs. Other medications should not be infused simultaneously with ZEMDRI through the same IV line.62",
    "statement_superscript": "62",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "lefamulin",
    "row_superscript": "1,63",
    "statement": "A single dose as an infusion equally distributed over 60 minutes. Do not exceed the recommended rate of administration; may increase the magnitude of QT prolongation. Do not add other additives to the diluent bag because their compatibilities with lefamulin have not been established.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "levofloxacin",
    "row_superscript": "1,64,65",
    "statement": "Temporarily discontinue other solutions infusing at the same site and flush tubing with compatible solutions before and after levofloxacin.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "lincomycin hydrochloride",
    "row_superscript": "1,66",
    "statement": "Manufacturer lists as incompatible with kanamycin and novobiocin. Manufacturer lists the following compatibilities. Infuse properly diluted solution at a rate not to exceed 100 mL/hr (1 Gm/hr).¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "linezolid",
    "row_superscript": "1,67",
    "statement": "Manufacturer lists as incompatible at the Y-site with amphotericin B (conventional), ceftriaxone (Rocephin), chlorpromazine (Thorazine), diazepam (Valium), erythromycin (Erythrocin), pentamidine, phenytoin (Dilantin), and sulfamethoxazole/trimethoprim.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "meropenem",
    "row_superscript": "1,68",
    "statement": "Meropenem should not be mixed or physically added to solutions containing other drugs; compatibility not established.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "metronidazole hydrochloride",
    "row_superscript": "1,69,70",
    "statement": "Administer separately, discontinue the primary IV during administration and do not introduce additives into the solution.¹ Local reactions include thrombophlebitis after intravenous infusion. This reaction can be minimized or avoided by avoiding prolonged use of indwelling intravenous catheters. 69 Administer by slow intravenous drip infusion only, either as a continuous or intermittent infusion. If used with a primary intravenous fluid system, the primary solution should be discontinued during metronidazole infusion.70",
    "statement_superscript": "1.69.70",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "minocycline hydrochloride",
    "row_superscript": "1,71",
    "statement": "Additives or other medications should not be added to the minocycline vial or infused simultaneously through the same IV line, including Y-connectors. If the same IV line is used for sequential infusion of additional medications, the line should be flushed before and after infusion of minocycline with NS, dextrose, dextrose in saline solutions, or LR.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "moxifloxacin hydrochloride",
    "row_superscript": "1,72",
    "statement": "Manufacturer states, \"Other IV substances, additives, or other medications should not be added to moxifloxacin or infused simultaneously through the same IV line.\" Flush line with a solution compatible to both drugs before and after administration of moxifloxacin and/or any other drug through the same IV line. May be administered through a Y-tube.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 9,
    "row_name": "nafcillin sodium",
    "row_superscript": "1,73",
    "statement": "Inactivated in solution with aminoglycosides (e.g., amikacin, gentamicin). Do not mix in the same solution. Appropriate spacing and/or separate sites required. May be infused over 5 to 10 minutes.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 10,
    "row_name": "omadacycline",
    "superscript_number": "1,74",
    "ph_value": null,
    "column_name": "Local site pain on Infusion.Absolute vein patency needed.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "oritavancin",
    "superscript_number": "1,75",
    "ph_value": "3.1-4.3",
    "column_name": "Phlebitis.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "oxacillin",
    "superscript_number": "1,76,77",
    "ph_value": "6-8.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "penicillin g aqueous",
    "superscript_number": "1,78",
    "ph_value": "5.5-8",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "piperacillin-tazobactam",
    "superscript_number": "1,79,80",
    "ph_value": "5.5-6.8",
    "column_name": "Phlebitis.Thrombo-phlebitis.Redness at injection site.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "rifampim",
    "superscript_number": "1,81",
    "ph_value": "7.8-8.8",
    "column_name": "Thrombo-phlebitis.Potential for damage from extravasation.Redness at injection site.Absolute vein patency needed.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "sulfamethoxazole- trimethoprim",
    "superscript_number": "1,82",
    "ph_value": "9.5-10.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain on Infusion.Rotation of peripheral infusion sites recommended.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "tedizolid",
    "superscript_number": "1,83",
    "ph_value": "7.4-8.1",
    "column_name": "Phlebitis.Potential for damage from extravasation.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "teicoplanin",
    "superscript_number": "84,85",
    "ph_value": "7.2-7.8",
    "column_name": "Phlebitis.Local site pain on Infusion.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "televancin",
    "superscript_number": "1,86",
    "ph_value": "4.5-5.0",
    "column_name": "Phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "ticarcillin & clavulanate",
    "superscript_number": "87,88",
    "ph_value": "5.5-7.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "tigecycline",
    "superscript_number": "1,89,90",
    "ph_value": "7.8",
    "column_name": "Phlebitis.Thrombo-phlebitis.Local site pain on Infusion.Redness at injection site.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "tobramycin",
    "superscript_number": "1,91,92",
    "ph_value": "3.0-6.5",
    "column_name": "Phlebitis.Thrombo-phlebitis.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.diamond"
  },
  {
    "page_number": 10,
    "row_name": "vancomycin",
    "superscript_number": "1,93,94,95",
    "ph_value": "2.5-5.0",
    "column_name": "Phlebitis.Thrombo-phlebitis.Potential for damage from extravasation.Local site pain on Infusion.Redness at injection site.Rotation of peripheral infusion sites recommended.Central line preferred.No simultaneous infusion/dedicated lumen",
    "mark_type": "circle.circle.circle.circle.circle.diamond.diamond"
  },
  {
    "page_number": 11,
    "row_name": "omadacycline",
    "row_superscript": "1,74",
    "statement": "Manufacturer states, \"Do NOT administer omadacycline with any solution containing multivalent cations (e.g., calcium and magnesium) through the same intravenous line. The compatibility of omadacycline with other drugs and infusion solutions other than D5W or NS has not been established.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "oritavancin",
    "row_superscript": "1,75",
    "statement": "Use only D5W for dilution. Do NOT use NS. NS is incompatible with oritavancin and may cause precipitation of the drug. Other IV substances, additives, or other medications mixed in NS should not be added to oritavancin single-use vials or infused simultaneously through the same IV line or through a common IV port. In addition, drugs formulated at a basic or neutral pH may be incompatible with oritavancin. If the same IV line is used for sequential infusion of additional medications, the line should be flushed before and after infusion of oritavancin with D5W.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "oxacillin",
    "row_superscript": "1,76,77",
    "statement": "Do not physically mix with other agents.\" May degrade in infusion solutions containing acidic agents. Inactivated in solution with aminoglycosides (e.g., amikacin, gentamicin). Do not mix in the same solution. Appropriate spacing and/or separate sites required. May be administered in specific IV solutions (check literature) over up to a 6-hour period. In injection 1 Gm (10 mL) or fraction thereof slowly over 10 minutes.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "penicillin g aqueous",
    "row_superscript": "1,78",
    "statement": "Do not mix in the same solution. Appropriate spacing and/or separate sites required. Do not mix in the same solution. Appropriate spacing and/or separate sites required. Administer as ordered as continuous IV drip; for example, 5 million units in 1,000 mL of D5W over 12 hour.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "piperacillin-tazobactam",
    "row_superscript": "1,79,80",
    "statement": "Should not be mixed with other drugs in a syringe or infusion bottle. Manufacturer recommends temporarily discontinuing other solutions infusing at the same site to avoid compatibility problems. Piperacillin may inactivate aminoglycosides (e.g., amikacin, gentamicin). Do not mix in the same solution. Separate administration required. Formulation containing EDTA may be compatible at the Y-site with amikacin or gentamicin. A single dose over 30 minutes as an intermittent infusion. Discontinue primary IV infusion during administration. Current data show that giving IV push over 2 to 3 minutes has been generally safe and tolerable when reconstituted with SWI 20 mL.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "rifampim",
    "row_superscript": "1,81",
    "statement": "\"May form a precipitate with diltiazem (Cardizem) at the Y-site.\" Infusion solutions other than D5W or NS are not recommended. A single dose diluted in 500 mL equally distributed as an infusion over 3 hours. In selected situations a single dose diluted in 100 mL may be administered over 30 minutes.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "sulfamethoxazole- trimethoprim",
    "row_superscript": "1,82",
    "statement": "Manufacturer states, \"Do not mix with other drugs or solutions.\" infusion. A single dose must be infused over 60 to 90 minutes. Avoid rapid infusion or bolus injection.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "tedizolid",
    "row_superscript": "1,83",
    "statement": "Other IV substances, additives, or other medications should not be added to tedizolid single-use vials or infused simultaneously through the same IV line or through a common IV port. If the same IV line is used for sequential infusion of additional medications, the line should be flushed before and after infusion of tedizolid with NS.\" It is incompatible with any solution containing divalent cations (e.g., calcium, magnesium), including LR injection and Hartmann's solution. Do not administer as an IV push or bolus.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "teicoplanin",
    "row_superscript": "84,85",
    "statement": "Solutions of teicoplanin and aminoglycosides are incompatible when mixed directly and should not be mixed before injection.85",
    "statement_superscript": "85",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "televancin",
    "row_superscript": "1,86",
    "statement": "Manufacturer states, \"Additives or other medications should not be added to telavancin single-use vials or infused simultaneously through the same IV line. If the same IV line is used for sequential infusion of additional medications, the line should be flushed before and after infusions of telavancin with D5W, NS, or LR. A single dose equally distributed as an infusion over 60 minutes.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "ticarcillin & clavulanate",
    "row_superscript": "87,88",
    "statement": null,
    "statement_superscript": null,
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "tigecycline",
    "row_superscript": "1,89,90",
    "statement": "The following drugs should not be administered simultaneously through the same Y-site as tigecycline: amphotericin B (conventional), amphotericin B lipid complex, diazepam, esomeprazole, and omeprazole .Flush IV line with D5W, NS, or LR before and after infusion of tigecycline if other drugs are administered through the same line.",
    "statement_superscript": null,
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "tobramycin",
    "row_superscript": "1,91,92",
    "statement": "Manufacturer states, \"Do not physically premix with other drugs; administer separately.\" Inactivated in solution with beta-lactam antibiotics (e.g., cephalosporins, penicillins) and vancomycin; do not mix in the same solution. Appropriate spacing required because of physical incompatibilities.¹",
    "statement_superscript": "1",
    "column_name": "Additional Consideration"
  },
  {
    "page_number": 11,
    "row_name": "vancomycin",
    "row_superscript": "1,93,94,95",
    "statement": "Administer continuous vancomycin infusions via a CVAD. In a small study, thrombophlebitis occurred in all patients receiving the infusion via a midline catheter, regardless of dilution, as assessed via daily ultrasound (IV). 93 Several sources recommend not admixing with other drugs. They suggest it is incompatible with alkaline solutions (e.g., aminophylline, aztreonam, barbiturates, chloramphenicol, dexamethasone, sodium bicarbonate) and may form a precipitate with heavy metals. May inactivate aminoglycosides; should also not be combined in the same solution with albumin, selected cephalosporins, foscarnet, or selected penicillins; if administered concurrently, administer at separate sites or separate intervals (flush IV line with a compatible solution before and after administration). A single dose properly diluted (concentration of no more than 5 mg/mL) at a rate not to exceed 10 mg/min or 60 minutes, whichever is longer. Another reference suggests each 500-mg increment over a minimum of 30 minutes.¹",
    "statement_superscript": "93.1",
    "column_name": "Additional Consideration"
  }
]